{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T20:57:16Z","timestamp":1783112236656,"version":"3.54.6"},"reference-count":13,"publisher":"Jaypee Brothers Medical Publishing","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.59556\/japi.73.1185","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T06:16:48Z","timestamp":1760509008000},"page":"e38-e41","source":"Crossref","is-referenced-by-count":1,"title":["Optimizing Proton-pump Inhibitor Therapy in Patients with Comorbidities Receiving Polypharmacy Treatment: Insights from Clinical Practice in India"],"prefix":"10.59556","volume":"73","author":[{"given":"Hemant T","family":"Juneja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Gambhir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khizer H","family":"Junaidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","reference":[{"issue":"(2):","key":"key20251015061643_B1","first-page":"109\u2013","article-title":"A cross-sectional study on single-day use of proton pump inhibitors in tertiary care hospitals of South India.","volume":"56","author":"ZA","year":"2021;","journal-title":"Hosp Pharm"},{"issue":"(6):","key":"key20251015061643_B2","first-page":"91\u2013","article-title":"Clinical practice of prescribing proton pump inhibitors by physicians: an Indian perspective.","volume":"119","author":"Desai","year":"2021;","journal-title":"J Indian Med Assoc"},{"issue":"(7):","key":"key20251015061643_B3","doi-asserted-by":"crossref","first-page":"e2419818.","DOI":"10.1001\/jamanetworkopen.2024.19818","article-title":"Navigating drug interactions with proton pump inhibitors.","volume":"7","author":"Tan","year":"2024;","journal-title":"JAMA Netw Open"},{"issue":"(4):","key":"key20251015061643_B4","doi-asserted-by":"crossref","first-page":"365\u2013","DOI":"10.1016\/j.jcin.2010.12.009","article-title":"Clopidogrel and proton pump inhibitors.","volume":"4","author":"Tantry","year":"2011;","journal-title":"JACC Cardiovasc Interv"},{"issue":"(4):","key":"key20251015061643_B5","doi-asserted-by":"crossref","first-page":"557\u2013","DOI":"10.1007\/s40119-023-00338-1","article-title":"Cardiovascular compatibility of proton pump inhibitors: practice recommendations.","volume":"12","author":"Dalal","year":"2023;","journal-title":"Cardiol Ther"},{"issue":"(3):","key":"key20251015061643_B6","doi-asserted-by":"crossref","first-page":"1\u2013","DOI":"10.9734\/ajmah\/2024\/v22i3986","article-title":"Expert opinion on the prescription practice of rabeprazole and other common proton pump inhibitors for patients with gastroesophageal reflux disease.","volume":"22","author":"Manjula","year":"2024;","journal-title":"Asian J Med Health"},{"issue":"(12):","key":"key20251015061643_B7","doi-asserted-by":"crossref","first-page":"3960.","DOI":"10.3390\/jcm12123960","article-title":"Risk of polypharmacy and its outcome in terms of drug interaction in an elderly population: a retrospective cross-sectional study.","volume":"12","author":"Alhumaidi","year":"2023;","journal-title":"J Clin Med"},{"issue":"(4):","key":"key20251015061643_B8","doi-asserted-by":"crossref","first-page":"201\u2013","DOI":"10.1007\/s40264-014-0144-0","article-title":"Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update.","volume":"37","author":"Wedemeyer","year":"2014;","journal-title":"Drug Saf"},{"issue":"(3):","key":"key20251015061643_B9","doi-asserted-by":"crossref","first-page":"266\u2013","DOI":"10.1016\/S0149-2918(00)80032-6","article-title":"The proton-pump inhibitors: similarities and differences.","volume":"22","author":"Horn","year":"2000;","journal-title":"Clin Ther"},{"issue":"(8):","key":"key20251015061643_B10","doi-asserted-by":"crossref","first-page":"509\u2013","DOI":"10.2165\/11531320-000000000-00000","article-title":"Drug\u2013drug interaction profiles of proton pump inhibitors.","volume":"49","author":"Ogawa","year":"2010;","journal-title":"Clin Pharmacokinet"},{"issue":"(40):","key":"key20251015061643_B11","doi-asserted-by":"crossref","first-page":"5097.","DOI":"10.3748\/wjg.15.5097","article-title":"Efficacy and safety of rabeprazole in non-steroidal anti-inflammatory drug-induced ulcer in Japan.","volume":"15","author":"Mizokami","year":"2009;","journal-title":"World J Gastroenterol"},{"issue":"(3):","key":"key20251015061643_B12","doi-asserted-by":"crossref","first-page":"228\u2013","DOI":"10.3164\/jcbn.15-1","article-title":"Long-term efficacy and safety of rabeprazole in patients taking low-dose aspirin with a history of peptic ulcers: a phase 2\/3, randomized, parallel-group, multicenter, extension clinical trial.","volume":"56","author":"Fujishiro","year":"2015;","journal-title":"J Clin Biochem Nutr"},{"issue":"(8):","key":"key20251015061643_B13","first-page":"879.e2\u2013","article-title":"Ability of rabeprazole to prevent gastric mucosal damage from clopidogrel and low doses of aspirin depends on CYP2C19 genotype.","volume":"10","author":"Uotani","year":"2012;","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T06:16:50Z","timestamp":1760509010000},"score":1,"resource":{"primary":{"URL":"https:\/\/japi.org\/article\/japi-73-10-e38"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.59556\/japi.73.1185"],"URL":"https:\/\/doi.org\/10.59556\/japi.73.1185","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}